Skip to main content

Table 3 Summary of Published Series of Patients with Severe Kawasaki Disease Treated with Cyclophosphamide

From: Cyclophosphamide use in treatment of refractory Kawasaki disease with coronary artery aneurysms

Article # of pnts Age at Dx Sex CYC dose Route CYC duration Prior Tx Follow up Outcome
Wallace CA et al, 2000 [9] 2 0.9 yr, 2.7 yrs. Male 2 mg/kg/day IV then PO 1.5-7mo IVIG, IVMP 2.5 yr and 2.8 yrs. Normal CAs at last follow up
Lucron H et al, 2004 [10] 4 0.3 yr, 0.8 yr, 2 yrs., 4.3 yrs 50% Male 10 mg/kg/day IV, then 2 mg/kg/day PO IV then PO IV 2–5 days, PO 6-12mo IVIG, Plasma-pheresis 8 yrs. and 13 yrs 2/4 deceased, both with myocarditis and CAAs
Briceno-Medina M et al, 2016 [11] 1 12 yrs. Male 15 mg/kg/day IV 4 doses IVIG, IVMP 3 yrs. + CAA, no stenosis or thrombosis
Current series, 2020 10 Median 2 yrs 50% Male 10 mg/kg/dose IV 1–2 doses IVIG, IVMP, IFX, CsA, ANA Median 2 yrs. 4mo Mean (median) z scores at last follow up: LAD 7.5 (5.0), RCA 8.3 (6.0)
  1. Pnts patients, Dx diagnosis, CYC cyclophosphamide, IV intravenous, PO oral, IVIG intravenous immunoglobulin, IVMP intravenous methylprednisolone, CAs coronary arteries, NL normal, CAA coronary artery aneurysms, z > 2.5, IFX infliximab, ANA anakinra, CsA cyclosporine A, LAD left anterior descending (proximal), RCA right coronary artery
\